Patents by Inventor Hidde L. Ploegh
Hidde L. Ploegh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11878063Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.Type: GrantFiled: March 5, 2020Date of Patent: January 23, 2024Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Ross Cheloha, Hidde L. Ploegh, Thomas J. Gardella
-
Patent number: 11850216Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.Type: GrantFiled: January 8, 2020Date of Patent: December 26, 2023Assignees: Whitehead Institute for Biomedical Research, The General Hospital CorporationInventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
-
Publication number: 20230348605Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.Type: ApplicationFiled: February 28, 2023Publication date: November 2, 2023Applicants: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical ResearchInventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu J. Xie
-
Publication number: 20230233701Abstract: Provided herein are compositions comprising VHH conjugates and their uses in treating diseases.Type: ApplicationFiled: June 2, 2021Publication date: July 27, 2023Applicant: Children's Medical Center CorporationInventors: Novalia Pishesha, Hidde L. Ploegh, Thibault Harmand
-
Patent number: 11597769Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.Type: GrantFiled: January 25, 2019Date of Patent: March 7, 2023Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical ResearchInventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu Joy Xie
-
Patent number: 11492590Abstract: Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.Type: GrantFiled: April 11, 2019Date of Patent: November 8, 2022Assignee: Whitehead Institute for Biomedical ResearchInventors: Lee Kim Swee, Hidde L. Ploegh
-
Publication number: 20220175833Abstract: Provided herein are engineered cells that comprising a chimeric antigen receptor comprising an extracellular target-binding moiety and an intracellular signaling domain; and secrets a heavy-chain antibody (VHH) or a VHH fusion protein. Methods of using the engineered cell to treat a disease (e.g., cancer or autoimmune disease) are also provided.Type: ApplicationFiled: March 6, 2020Publication date: June 9, 2022Applicants: Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: Yushu J. Xie, Hidde L. Ploegh
-
Patent number: 11266695Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.Type: GrantFiled: March 23, 2018Date of Patent: March 8, 2022Assignee: Whitehead Institute for Biomedical ResearchInventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Sherry Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
-
Publication number: 20220032257Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: ApplicationFiled: September 20, 2021Publication date: February 3, 2022Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 11154833Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: October 25, 2018Date of Patent: October 26, 2021Assignee: President and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 11028185Abstract: Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein.Type: GrantFiled: September 24, 2018Date of Patent: June 8, 2021Assignee: Whitehead Institute for Biomedical ResearchInventors: Hidde L. Ploegh, Martin D. Witte, Nicholas C. Yoder
-
Publication number: 20200384137Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.Type: ApplicationFiled: January 8, 2020Publication date: December 10, 2020Applicants: Whitehead Institute for Biomedical Research, The General Hospital CorporationInventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
-
Publication number: 20200316217Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.Type: ApplicationFiled: March 5, 2020Publication date: October 8, 2020Applicants: Children's Medical Center Corporation, The General Hospital CorporationInventors: Ross Cheloha, Hidde L. Ploegh, Thomas J. Gardella
-
Publication number: 20200206269Abstract: Multi-step methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express fusion proteins comprising an antigen binding protein which allows the red blood cell to bind a toxin or an antigen of a pathogen. Also described herein are methods for neutralizing a toxin or pathogen in a subject by administering enucleated red blood cells that express any of the fusion proteins provided herein.Type: ApplicationFiled: August 22, 2018Publication date: July 2, 2020Applicants: Whitehead Institute for Biomedical Research, Trustees of Tufts CollegeInventors: Harvey Lodish, Nai-Jia Huang, Novalia Pishesha, Hidde L. Ploegh, Charles Shoemaker
-
Publication number: 20200069736Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.Type: ApplicationFiled: September 16, 2019Publication date: March 5, 2020Applicant: Whitehead Institute for Biomedical ResearchInventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
-
Patent number: 10556024Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolalebed proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.Type: GrantFiled: November 13, 2014Date of Patent: February 11, 2020Assignees: Whitehead Institute for Biomedical Research, The General Hospital CorporationInventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
-
Publication number: 20190359933Abstract: Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.Type: ApplicationFiled: April 11, 2019Publication date: November 28, 2019Applicant: Whitehead Institute for Biomedical ResearchInventors: Lee Kim Swee, Hidde L. Ploegh
-
Patent number: 10471099Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.Type: GrantFiled: May 9, 2014Date of Patent: November 12, 2019Assignee: Whitehead Institute for Biomedical ResearchInventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
-
Publication number: 20190256818Abstract: Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.Type: ApplicationFiled: February 15, 2019Publication date: August 22, 2019Applicant: Whitehead Institute for Biomedical ResearchInventors: Lee Kim Swee, Hidde L. Ploegh
-
Patent number: 10260038Abstract: Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to nongenetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g. a method of modulating an immune response of a subject to an entity of interest, a method of neutralizing a substance in the body of a subject, a method of treating a subject in need of treatment for deficiency of a protein, and a method of treating a subject in need of treatment for a disease, are provided.Type: GrantFiled: May 9, 2014Date of Patent: April 16, 2019Assignee: Whitehead Institute for Biomedical ResearchInventors: Lee Kim Swee, Hidde L. Ploegh